This past March, Health Canada published final regulations allowing for public release of submitted clinical information on drugs and medical devices. Since then, Health Canada has posted information for four newly approved drugs. The EMA enacted a similar policy in the EU four years ago. Will US FDA follow suit?
Want to dig deeper into data transparency and disclosure?
-
Article
EMA/FDA Question Time
Read Now
Chris M. Slawecki, DIA
Global Forum -
Article
Evaluating the Completeness of ClinicalTrials.gov
Read Now
Stella Stergiopoulos et al.
Therapeutic Innovation & Regulatory Science
Member-only content
-
Article
Clinical Trial Development, Transparency, and Medical Information
Read Now
Sandra Blumenrath, DIA
Global Forum -
Article
The Exciting Future of Pharmacovigilance
Read Now
Chris M. Slawecki, DIA
Global Forum -
Article
Reporting of Randomized Clinical Trials Remains Far from Optimal
Read Now
J. Rick Turner
Therapeutic Innovation & Regulatory Science
Member-only content
-
Podcast
HHS Final Rule: Good Data Shared Well Leads to Great Science
Listen Now
Marla Jo Brickman, Pfizer
Related Perspectives
View all Deep Dives-
Article
From Privacy Analytics: Early Impact of Health Canada’s New Guidelines
Read Now -
White Paper
From STAT News: Pharma continues to get poor grades when it comes to sharing clinical trial data
Read Now